Rodney Lyle Johnson
Affiliations: | 1979- | Medicinal Chemistry | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Peptidomimetics, dopamine receptors, allosteric modulatorsWebsite:
https://www.pharmacy.umn.edu/bio/cop-experts/rodney-johnsonGoogle:
"Rodney Lyle Johnson"Mean distance: (not calculated yet)
Parents
Sign in to add mentorEdward Ervin Smissman | grad student | 1974 | University of Kansas | |
Gary L. Grunewald | grad student | 1976 | University of Kansas | |
(A study of the structural requirements for dopa potentiation by the hypothalamic hormone L-prolyl-L-leucylglycinamide.) |
Children
Sign in to add traineeSarika V. Prabhu | grad student | 2002 | UMN |
Abigail L. Fisher | grad student | 2005 | UMN |
Bhooma Raghavan | grad student | 2006 | UMN |
Ashish P. Vartak | grad student | 2006 | UMN |
Cory Kending | grad student | 2008 | UMN |
Swapna Bhagwanth | grad student | 2009 | UMN |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Basu D, Tian Y, Hui P, et al. (2015) Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA. Peptides. 66: 58-62 |
Basu D, Tian Y, Bhandari J, et al. (2013) Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization. Plos One. 8: e70736 |
Tan ML, Basu D, Kwiecien JM, et al. (2013) Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia. Peptides. 42: 89-96 |
Bhagwanth S, Mishra RK, Johnson RL. (2013) Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor. Beilstein Journal of Organic Chemistry. 9: 204-14 |
Beyaert MG, Daya RP, Dyck BA, et al. (2013) PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 253-62 |
Bhagwanth S, Mishra S, Daya R, et al. (2012) Transformation of Pro-Leu-Gly-NH2 peptidomimetic positive allosteric modulators of the dopamine D2 receptor into negative modulators. Acs Chemical Neuroscience. 3: 274-84 |
Dyck B, Guest K, Sookram C, et al. (2011) PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia. Schizophrenia Research. 125: 88-92 |
Mann A, Verma V, Basu D, et al. (2010) Specific binding of photoaffinity-labeling peptidomimetics of Pro-Leu-Gly-NH2 to the dopamine D2L receptor: evidence for the allosteric modulation of the dopamine receptor. European Journal of Pharmacology. 641: 96-101 |
Wood RL, Young-Dixon BJ, Roy A, et al. (2010) Evaluation of Density Functionals, SCC-DFTB, Neglect of Diatomic Differential Overlap (NDDO) Models and Molecular Mechanics Methods for Prolyl-Leucyl-Glycinamide (PLG) and Structural Derivatives. Theochem. 944: 76-82 |
Raghavan B, Skoblenick KJ, Bhagwanth S, et al. (2009) Allosteric modulation of the dopamine D2 receptor by Pro-Leu-Gly-NH2 peptidomimetics constrained in either a polyproline II helix or a type II beta-turn conformation. Journal of Medicinal Chemistry. 52: 2043-51 |